https://www.taxtmi.com/caselaws?id=222039 The court dismissed the plaintiffs' application for interim relief in a patent infringement case involving the molecule "SITAGLIPTIN." The court found that the plaintiffs failed to demonstrate the differences in treating Type-II Diabetes between SITAGLIPTIN alone and the defendant's product containing SITAGLIPTIN with phosphate. Additionally, the court noted the plaintiffs' lack of disclosure regarding their abandoned patent application for Sitagliptin Phosphate, which led to the denial of interim relief. The court highlighted the presence of other companies marketing similar products as a factor in rejecting the plaintiffs' claim for irreparable injury and balance of convenience. en-us Fri, 05 Apr 2013 00:00:00 +0530 Thu, 11 Apr 2013 13:51:00 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=222039 The court dismissed the plaintiffs' application for interim relief in a patent infringement case involving the molecule "SITAGLIPTIN." The court found that the plaintiffs failed to demonstrate the differences in treating Type-II Diabetes between SITAGLIPTIN alone and the defendant's product containing SITAGLIPTIN with phosphate. Additionally, the court noted the plaintiffs' lack of disclosure regarding their abandoned patent application for Sitagliptin Phosphate, which led to the denial of interim relief. The court highlighted the presence of other companies marketing similar products as a factor in rejecting the plaintiffs' claim for irreparable injury and balance of convenience. Case-Laws Companies Law Fri, 05 Apr 2013 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=222039